Drug Profile
Research programme: immunotherapeutic vaccines - UbiVac
Alternative Names: DPV-003HPV; DPV-004Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator UbiVac
- Class Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 12 Sep 2016 UbiVac plans a phase II trial for DPV 002 in Breast cancer (Combination therapy) in USA (UbiVac pipeline, September 2016)
- 28 Oct 2015 Preclinical trials in Cancer in USA (Parenteral) before October 2015 (UbiVac pipeline, october 2015)